This article was originally published in Start Up
Executive SummaryGenomics; Bioinformatics. Alphagene intends to use its abilities to speedily find full-length genes and determine that they are indeed novel and disease-related on behalf of Big Pharma clients. The company will use its original analytical software, itsmethod for building gene libraries, and its robotic system for determining which genes are turned off or on in normal and diseased tissue to work with drugmakers working in defined disease areas (rather than selling its set of tools to clients).
You may also be interested in...
Outsourcing is not just for mundane pharma services anymore. Increasingly, drugmakers are contracting for specialized R&D assistance they expect to provide strategic as well as tactical advantages.
Like other companies investigating entirely new ways of treating bacterial infections, biotech start-up Spero is increasingly aware that novel antibiotics may need to travel new clinical and regulatory pathways to market.
RxMP Therapeutics LLC is working to resolve excessive diffuse bleeding that is often associated with trauma, and also with certain orthopedic and cardiovascular surgeries. The start-up believes it can successfully treat excessive diffuse bleeding with particles produced from the membranes of red blood cells that have been freeze-dried and then, literally, blown to bits.